| Interaction Color Code | Clinical Bottom Line | Clinical Effects | Drug 1 effect | Drug 2 dose | Drug 2 effect | Management | |
|---|---|---|---|---|---|---|---|
| Dolutegravir INH 113 | Red: Avoid combination | Do not coadminister: Increased levels of izoniazid and reduced levels of dolutegravir | Potential for increased adverse effects of isoniazid (flu-like symptoms, nausea, vomiting, and fever) |
AUC decreased 46%, Cmin decreased 74% |
15 mg / kg + rifapentine 900 mg once weekly | INH AUC increased 67-92% in 2 / 4 subjects. Rifapentine no significant change. |
Use alternative agents |
